ClinicalTrials.gg
Not yet recruitingNCT07714070PKUPH-ORLPP-ECUpdated Jul 20, 2026

Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia

A Phase 2 interventional study of Orlistat and Progestin in Endometrial Neoplasms, Endometrial Cancer and Atypical Endometrial Hyperplasia, sponsored by Peking University People's Hospital. Not yet recruiting at 1 site in China. Open to female participants aged Up to 46 Years. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by Peking University People's Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
Up to 46 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Endometrial Neoplasms by Peking University People's Hospital — 15 open to participants now, 15 under way, none of them phase 3. Endometrial Neoplasms · Peking University People's Hospital.

Planned enrollment
15th of 18
48 · median 94
Started
2026
the only one that year
Phase 2
5 of 19
5 open now
Primary completion
2027-09
later than 10 of 14 live
Registered
18th of 19
by date

Among the 19 studies in Endometrial Neoplasms by Peking University People's Hospital, this one is the 15th largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2026, is one of 5 in phase 2, reaches primary completion later than 10 of the 14 other live ones, and was the 18th registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

15 of the 19 studies in Endometrial Neoplasms by Peking University People's Hospital are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: Up to 46 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Endometrial Neoplasms by Peking University People's Hospital, or all of them as a file.
02

Study summary

This is a single-center, randomized, open-label, controlled clinical trial evaluating whether adding orlistat to standard progestin therapy can improve treatment response in patients receiving fertility-sparing treatment for early-stage endometrial cancer (grade 1-2) or atypical endometrial hyperplasia.

Progestin is the standard drug used to preserve the uterus and fertility in these patients, but about 30% of patients respond poorly because the progesterone receptor (PR) in the endometrium is lost or reduced. Laboratory studies by the research team have shown that orlistat, a widely used oral weight-loss drug that blocks fat absorption, can raise PR levels and restore sensitivity to progestin.

The study will enroll 48 patients (age 45 years or younger, body mass index 24 kg/m2 or higher) who still have residual disease and low PR expression after at least 3 months of first-line progestin therapy. Participants will be randomly assigned in a 1:1 ratio to receive either progestin plus orlistat (experimental group) or progestin alone (control group) for 3 months, followed by 24 months of follow-up. The main goal is to compare the change in PR expression from baseline after 3 months of treatment. The study will also assess how many patients achieve complete disease reversal, time to complete response, recurrence, pregnancy and live-birth rates, safety, and changes in body weight and metabolic measures.

Read the detailed description

Background and rationale:

Endometrial cancer (EC) is one of the most common gynecologic malignancies, and 14% to 25% of cases occur in women of reproductive age, many of whom wish to preserve fertility. Progestin is the first-line agent for fertility-sparing treatment of grade 1-2 endometrioid EC and atypical endometrial hyperplasia (AEH), with reported complete response (CR) rates up to 84%. However, approximately 30% of patients show primary or secondary progestin resistance, and loss or down-regulation of the progesterone receptor (PR) is a key mechanism. Obesity is both an independent risk factor for EC and associated with poor progestin response, while progestin itself commonly causes weight gain, creating a vicious cycle of obesity, reduced efficacy, and further weight gain.

Orlistat is an FDA-approved oral gastrointestinal lipase inhibitor widely used for weight management. Beyond weight loss, preclinical studies have shown antitumor activity across several cancer types through inhibition of fatty acid synthase (FASN). The research team previously established a lipid metabolism-FOXA2-PR transcriptional regulatory axis in EC (Liu et al., Oncogene 2025), demonstrating that orlistat stabilizes FOXA2 by inhibiting AKT phosphorylation, thereby up-regulating PR transcription and restoring progestin sensitivity in xenograft models. This trial is the first prospective randomized controlled trial to evaluate orlistat as a transcriptional sensitizer in fertility-sparing treatment of EC/AEH.

Study design:

This is a single-center, prospective, randomized, open-label, parallel-controlled trial conducted at Peking University People's Hospital. Forty-eight eligible patients with G1-G2 endometrioid EC or AEH who have low PR expression (positive cells 25% or less) and have not achieved CR after at least 3 months of first-line progestin therapy are randomized in a 1:1 ratio to the experimental group (progestin plus oral orlistat 120 mg three times daily) or the control group (progestin alone). High-potency progestin (medroxyprogesterone acetate 250-500 mg/day or megestrol acetate 160-320 mg/day) is individualized by the investigator according to body weight, liver function, and prior dose. Randomization uses a computer-generated sequence (SAS 9.4) concealed in sequentially numbered sealed opaque envelopes.

The treatment period is 3 months, followed by 24 months of follow-up. Endometrial biopsy by hysteroscopy is performed every 3 months to evaluate histopathologic response, with paired tissue sampling for translational endpoints (PR, FOXA2, and phospho-FOXA2 immunohistochemistry; bulk RNA sequencing; and peripheral blood lipid metabolomics). The primary endpoint is the relative change in PR expression from baseline at 3 months. A pre-planned interim futility analysis using an O'Brien-Fleming alpha-spending function is performed when 50% of participants are enrolled, overseen by a Data and Safety Monitoring Board.

03

Conditions studied

  • Endometrial Neoplasms
  • Endometrial Cancer
  • Atypical Endometrial Hyperplasia
  • Progestin Resistance

Keywords

  • Fertility Preservation
  • Fertility-Sparing Treatment
  • progestin
  • orlistat
  • progesterone receptor
04

Who can participate

Ages eligible
Up to 46 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed grade 1-2 endometrioid endometrial adenocarcinoma or atypical endometrial hyperplasia (AEH), independently confirmed by two senior pathologists
  • Lesion confined to the endometrium on MRI or transvaginal ultrasound; FIGO (2009) stage IA without myometrial invasion (for G1, superficial invasion less than one half is allowed; G2 must have no myometrial invasion)
  • Age 45 years or younger
  • Received MPA 250-500 mg/day or MA 160-320 mg/day for at least 3 months, with hysteroscopy plus curettage confirming failure to achieve complete response (persistent EC/AEH lesion)
  • PR-positive cell percentage 25% or less and intensity grade 1 or lower (0 negative, 1 weak, 2 moderate, 3 strong), independently judged by two senior pathologists with a third adjudicating any disagreement
  • 24 kg/m2 or higher; no severe comorbidity, specifically /AST 2.5x or lower, serum creatinine 1.5x ULN or lower, and no history of active gastrointestinal bleeding
  • No to progestin therapy or to pregnancy
  • No evidence of distant on pelvic MRI and chest/abdominal CT
  • Clearly wishes to preserve fertility and provides signed
  • No use of orlistat or other lipase inhibitors within the past 6 months
  • Willing and able to comply with follow-up at this hospital

Exclusion criteria

Exclusion Criteria:

  • Tumor invading more than one half of the myometrium; FIGO (2009) stage IB or higher
  • Grade G3 or non-endometrioid histology (serous, clear cell, carcinosarcoma, etc.)
  • Coexisting other endometrial cancer or other reproductive-system ; coexisting breast cancer or other hormone-dependent tumor precluding progestin use
  • Allergy to orlistat or any formulation component, or prior severe adverse reaction (including severe hepatic injury) to orlistat
  • Chronic malabsorption syndrome (Crohn disease, celiac disease, short bowel syndrome) or cholestasis
  • Concurrent use of ciclosporin, warfarin, levothyroxine, antiepileptics (carbamazepine, phenytoin), or amiodarone that interact significantly with orlistat and cannot be replaced or dose-adjusted
  • Planned bariatric surgery (gastric bypass, sleeve gastrectomy, etc.) during the study
  • Pregnancy or lactation; unwilling to use reliable during the study and for 3 months after study completion
  • Poor compliance or unable to complete 24 months of follow-up
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Orlistat Plus Progestin

    Participants receive high-potency progestin (medroxyprogesterone acetate 250-500 mg/day or megestrol acetate 160-320 mg/day, dose individualized by the investigator) combined with oral orlistat 120 mg three times daily, taken with meals or within 1 hour after a meal, for 3 months.

    Drug: Orlistat · Drug: Progestin

  • Active comparator
    Progestin Alone

    Participants receive high-potency progestin alone (medroxyprogesterone acetate 250-500 mg/day or megestrol acetate 160-320 mg/day, dose individualized by the investigator) for 3 months.

    Drug: Progestin

Interventions

  • Oral orlistat 120 mg three times daily, taken with meals or within 1 hour after a meal, for 3 months. A dose may be omitted if a meal is skipped or contains no fat.

  • DrugProgestinsStudies of ProgestinsProgestins pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    High-potency progestin given orally as background therapy in both groups: medroxyprogesterone acetate 250-500 mg/day or megestrol acetate 160-320 mg/day, with the specific agent and dose individualized by the investigator based on body weight, liver function, and prior dose.

06

What researchers measure

Primary outcomes

  1. Relative change in progesterone receptor (PR) expression from baseline at 3 months (delta PR%)

    Relative change in PR expression measured by immunohistochemistry (H-score or percentage of PR-positive cells) in endometrial tissue obtained by hysteroscopic biopsy at 3 months versus baseline. An effective PR increase is defined as delta PR% \>= 1%, calculated as (PR at 3 months minus PR at baseline) / PR at baseline x 100%.

    Time frame: Baseline and 3 months (90 +/- 7 days after randomization)

Secondary outcomes

  1. Pathological complete response rate at 3 months

    Proportion of participants achieving complete response (CR), defined as complete reversal of the endometrium to normal proliferative or secretory endometrium with no residual endometrial cancer or atypical hyperplasia, assessed by hysteroscopic biopsy and curettage and judged independently by two blinded pathologists.

    Time frame: 3 months (90 +/- 7 days after randomization)

  2. Pathological complete response rate at 6 months

    Proportion of participants achieving pathological complete response at 6 months, assessed by hysteroscopic biopsy and curettage.

    Time frame: 6 months (180 +/- 7 days after randomization)

  3. Relative change in PR expression from baseline at 6 months (delta PR%)

    Relative change in PR immunohistochemistry H-score in paired endometrial tissue at 6 months versus baseline.

    Time frame: Baseline and 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the published results, together with the data dictionary, will be made available to qualified researchers whose proposed use has been approved by the study team.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Beginning 6 months and ending 36 months after publication of the primary results.

Access criteria: Requests should be directed to the principal investigator. Requesters will be asked to sign a data access agreement, and each proposal will be reviewed and approved by the study team and the sponsor institution before data are released.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Sep 2027, 14 months later.

Of 109 non-industry phase 2 interventional studies under Endometrial Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 115. This study's planned 14 months is below that.

Counting every sponsor, half of 141 studies reached it within 55 months; a quarter within 37 and three quarters within 115.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2026
First posted
Jul 20, 2026
StartEst.
Jul 2026
Primary completionEst.
Sep 2027
CompletionEst.
Dec 2029
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07714070
Responsible party
Wang Jianliu (Professor and Chief Physician, Department of Obstetrics and Gynecology, Peking University People's Hospital) — Principal investigator
First posted
Jul 20, 2026
Start date
Jul 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Dec 2029 (estimated)
Last update
Jul 20, 2026

Study contacts

Jian liu Wang, MD
Contact
wangjianliu1203@163.com
861088324075
Jie Liu, PhD
Contact
liu19801118612@163.com
+8619801118612

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orlistat

Start the discussion